<DOC>
	<DOCNO>NCT00484185</DOCNO>
	<brief_summary>To provide safety effectiveness information BeneFIX post-marketing period require Korea FDA regulation , identify potential drug relate treatment factor Korean population include : 1 ) Unknown adverse reaction , especially serious adverse reaction ; 2 ) Changes incidence adverse reaction routine drug us . 3 ) Factors may affect safety drug 4 ) Factors may affect effectiveness drug</brief_summary>
	<brief_title>Post Marketing Surveillance To Observe Safety Efficacy Of BeneFIX In Patients With Hemophilia B</brief_title>
	<detailed_description>The patient meet inclusion criterion enrol consecutively .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Patients legally authorize representative pediatric patient agree provide write informed consent form ( data privacy statement ) . Pediatric adult patient treat original reformulated BeneFIX hemophilia B ( congenital factor IX deficiency Christmas disease ) first approve date KFDA , plan newly prescribe BeneFIX ( example , patient switch pdFIX BeneFIX ) . Patients known history hypersensitivity original reformulate BeneFIX component product . Patients known history hypersensitivity hamster protein . Patients participate interventional trial investigational drug device .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Hemophilia B</keyword>
	<keyword>BeneFIX</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
</DOC>